『Treatment of hypertension accompanied by diabetes and obesity

Release of the optimal ARB ‘Telcadin Series’』

 

 

As of March 1, 2013, KyungDong Pharm Co., Ltd. releases the “Telcadin Series,” an ARB blood pressure lowering agent containing telmisartan.

The “Telcadin Series” contains Telmisartan as the main ingredient and is released as a total of four products: ‘Telcadin Tablets 40mg’, ‘Telcadin Tablets 80mg’, and diuretic combination drugs ‘Telcadin Plus Tablets’ and ‘Telcadin Plus F Tablets’.

 

The “Telcadin Series” has the advantage of being effective in lowering blood pressure in the early morning, lowering the risk of cardiovascular disease in patients with high blood pressure accompanied by diabetes and obesity. In addition, it has been proven to protect renal function and inhibit the occurrence of cardiovascular disease, which lowers the incidence of complications due to high blood pressure.

 

KyungDong Pharm Co., Ltd. is expected to further solidify its position as a specialized company in the treatment of hypertension with the launch of the “Telcadin Series,” following the “Rosata Series,” “Cansata Series,” and “Valtrep Series,” which are ARB-based hypertension treatments.

   

 

 

 

♤ Product Information ♤

Category

Telcadine tablets 40mg

Telcadine tablets 80mg

Telcardin Plus Tablets

Telcadin Plus F Tablet

Ingredient content

telmisartan 40mg

telmisartan 80mg

telmisartan 40mg

Hydrochlorothiazide 12.5mg

telmisartan 80mg

Hydrochlorothiazide 12.5mg

Appearance

A white or off-white, elongated oval tablet.

An oblong tablet with two layers, one white and one red.

Indications

1. Essential hypertension

2. Reduced risk of cardiovascular disease

Treatment of essential hypertension

Patients whose blood pressure is not adequately controlled by telmisartan alone

Packaging unit

30 tablets

Reimbursement Code

648103200

648103190

648103210

648103220

 

※ Please refer to the product manual for other details such as dosage, precautions for use, etc.